Excess ICU Mortality Attributable to Ventilator-associated Pneumonia: the Role of Early Vs Late Onset
Overview
Affiliations
Objective: To determine the impact of ventilator-associated pneumonia (VAP) on ICU mortality, and whether it is related to time of onset of pneumonia.
Design: Prospective cohort study.
Setting: 16-bed medical-surgical ICU at a university-affiliated hospital.
Patients And Measurements: From 2002 to 2003, we recorded patients receiving mechanical ventilation for > 72 h. Patients developing an infection other than VAP were excluded. Patients definitively diagnosed with VAP (n=40) were cases and patients free of any infection acquired during ICU stay (n=61) were controls. The VAP-attributed mortality was defined as the difference between observed mortality and predicted mortality (SAPS II) on admission.
Results: Mechanical ventilation was longer in VAP patients (25 +/- 20 vs 11 +/- 9 days; p < 0.001), as was ICU stay (33 +/- 23 vs 14 +/- 12 days; p < 0.001). In the non-VAP group, no difference was found between observed and predicted mortality (27.9 vs 27.4%; p > 0.2). In the VAP group, observed mortality was 45% and predicted mortality 26.5% (p < 0.001), with attributable mortality 18.5%, and relative risk (RR) 1.7 (95% CI 1.12-23.17). No difference was observed between observed and predicted mortality in early-onset VAP (27.3 vs 25.8%; p > 0.20); in late-onset VAP, observed mortality was higher (51.7 vs 26.7%; p < 0.01) with attributable mortality of 25% and an RR 1.9 (95% CI 1.26-2.63). Empiric antibiotic treatment was appropriate in 77.5% of episodes. No differences in mortality were related to treatment appropriateness.
Conclusions: In mechanically ventilated patients, VAP is associated with excess mortality, mostly restricted to late-onset VAP and despite appropriate antibiotic treatment.
Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges.
Howroyd F, Chacko C, MacDuff A, Gautam N, Pouchet B, Tunnicliffe B Nat Commun. 2024; 15(1):6447.
PMID: 39085269 PMC: 11291905. DOI: 10.1038/s41467-024-50805-z.
Hurley J Antibiotics (Basel). 2024; 13(4).
PMID: 38666992 PMC: 11047347. DOI: 10.3390/antibiotics13040316.
Abdelkarim O, Abubakar U, Taha L, Ashour S, Abass W, Osman E Infect Drug Resist. 2023; 16:7209-7217.
PMID: 38023395 PMC: 10656842. DOI: 10.2147/IDR.S378645.
Dobakhti F, Eskandari M, Tavakolizadeh M, Forouzideh N, Dobakhti P, Jamshidi M Tanaffos. 2023; 22(1):112-119.
PMID: 37920313 PMC: 10618586.
Daghmouri M, Dudoignon E, Chaouch M, Baekgaard J, Bougle A, Leone M EClinicalMedicine. 2023; 58:101880.
PMID: 36911269 PMC: 9995933. DOI: 10.1016/j.eclinm.2023.101880.